Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

Where Amgen Stands With Analysts

Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

Here's a roundup of top developments in the biotech space over the last 24 hours:

Dow Jones Rallies As Facebook Soars 18% On Earnings; Apple Earnings Due

Dow Jones Rallies As Facebook Soars 18% On Earnings; Apple Earnings Due

The Dow Jones Industrial Average jumped Thursday, as Facebook soared 18% on earnings results. Apple earnings are due after the market closes.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure

Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015.

Recap: Amgen Q1 Earnings

Amgen (NASDAQ:AMGN) reported its Q1 earnings results on Wednesday, April 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amgen beat estimated earnings by 2.41%, reporting an EPS of $4.25 versus an estimate of $4.15.

Biotech Behemoth Amgen Tops First-Quarter Views, But 2022 Guidance Lags

Amgen stock fell late Wednesday on a surprise in its 2022 outlook despite a strong first-quarter showing with earnings and sales above views.

Investors Business Daily

Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen

Molecular Partners AG's (NASDAQ:MOLN) collaborating partner Amgen Inc (NASDAQ:AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review. MP0310 is a dual-targeted compound targeting both FAP and 4-1BB that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming…

inkl

Read news from The Economist, FT, and more,
with one subscription

Earnings Preview: Amgen

Earnings Preview: Amgen

Amgen (NASDAQ:AMGN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Amgen will report an earnings per share (EPS) of $4.15.

If You Invested $100 In Amgen 15 Years Ago, Here's How Much You Would Have Today

If You Invested $100 In Amgen 15 Years Ago, Here's How Much You Would Have Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.31% on an annualized basis producing an average annual return of 9.87%. Currently, Amgen has a market capitalization of $136.97 billion.

Revealed: Hundreds of millions in UK taxpayers’ money handed to companies still operating in Russia

Revealed: Hundreds of millions in UK taxpayers’ money handed to companies still operating in Russia

Exclusive: British government accused of indirectly helping to fund Putin’s war with £294m contracts

The Independent UK

Where Amgen Stands With Analysts

Where Amgen Stands With Analysts

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

Amgen's Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer

Amgen's Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer

Amgen Inc (NASDAQ:AMGN) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7%,…

$1000 Invested In Amgen 10 Years Ago Would Be Worth This Much

$1000 Invested In Amgen 10 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.13% on an annualized basis producing an average annual return of 13.98%. Currently, Amgen has a market capitalization of $136.43 billion.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.42% on an annualized basis.

Get all your
news in one place.

100’s of premium titles.
One news app.

A Bullish Sign Appears On Amgen's Chart

If history is any guide, there may be good fortune ahead for shares of Amgen (NASDAQ:AMGN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer

Amgen Inc (NASDAQ: AMGN) announced the presentation of

This Is What Whales Are Betting On Amgen

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

What 10 Analyst Ratings Have To Say About Amgen

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

What Are Whales Doing With Amgen

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Investors Business Daily

Dow Jones Jumps 350 Points, Fueled By Amgen Breakout; Financial Stocks Follow 10-Year Yield Higher

The Dow Jones Industrial showed a solid gain in afternoon trading Tuesday. Amgen, American Express and JPMorgan outperformed.

Amgen's Q4 Sales Remain Flat As Its Biggest Product Flounders

Amgen Inc's (NASDAQ: AMGN) Q4 revenues incr

What's Going On With Amgen Stock During Today's After-Hours Session

Shares of Amgen Inc. (NASDAQ: AMGN) stepped higher following the release of its Q4 earnings report showing an EPS beat and a slight miss on sales.

Amgen: Q4 Earnings Insights

Amgen (NASDAQ:AMGN) reported its Q4 earnings results on Monday, February 7, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amgen beat estimated earnings by 5.83%, reporting an EPS of $4.36 versus an estimate of $4.12.

Investors Business Daily

Amgen Gaps Higher On Bullish 2030 Outlook; Why Some Are Questioning It

Amgen stock gapped up Tuesday after the company issued bullish guidance for 2030, though investors were split on whether it's achievable.

A Preview Of Amgen's Earnings

Amgen (NASDAQ:AMGN) is set to give its latest quarterly earnings report on Monday, 2022-02-07. Here's what investors need to know before the announcement. Analysts estimate that Amgen will likely report an Earnings Per Share (EPS) of $4.12.

1 … 10 11 12 13

People

Lesia Vasylenko

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

American Express

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

236,996 stories

100,216 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play